[Hong Kong Stock Connect] SHANDONG XINHUA (00719) has received registration approval from the National Medical Products Administration for empagliflozin tablets, which are suitable for the treatment of type 2 diabetes.

Jinwu Financial News | SHANDONG XINHUA (00719) announced that the company recently received the Drug Registration Certificate for Empagliflozin Tablets (10mg) approved and issued by the National Medical Products Administration. This product meets the relevant requirements for drug registration and is approved for registration. Empagliflozin Tablets are indicated for the treatment of type 2 diabetes; they are used in adult patients with symptomatic chronic heart failure to reduce the risk of hospitalization due to heart failure.

Jingwu Financial News04:12 ET

SHANDONG XINHUA (00719.HK): The empagliflozin tablets (10mg) have obtained the pharmaceutical registration certificate.

On January 21, Gelonghui reported that SHANDONG XINHUA (00719.HK) announced that the company recently received the Drug Registration Certificate for Empagliflozin Tablets (10mg) (hereinafter referred to as "the product") issued by the National Medical Products Administration. This product meets the relevant requirements for drug registration and is approved for registration. In June 2023, Shandong Xinhua Pharmaceutical submitted the registration application for the market approval of Empagliflozin Tablets (10mg) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration and received acceptance. The Drug Registration Certificate was obtained in January 2025, with the review conclusion being approved for registration. Empagliflozin is developed by Boehringer Ingelheim.

Gelonghui Finance03:34 ET

Express News | Shandong Xinhua Pharmaceutical - Empagliflozin Tablets (10Mg) Obtained Drug Registration Certificate by China Nmpa

Reuters03:31 ET

SHANDONG XINHUA (00719) has received the "Pharmaceutical Supplement Application Approval Notice" for Rosuvastatin Calcium Tablets (20mg; 10mg).

SHANDONG XINHUA (00719) announced that recently, the company received approval from the National Medical Products Administration for the issuance of Ruishu...

Zhitong Finance03:31 ET

China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.

National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.

Zhitong Finance18:54 ET

Shandong Xinhua Pharmaceutical Secures Approval for Drug Marketing Authorization Transfer

TipRanksJan 20 04:10 ET